Delivery Order SPE2DR25D2006-SPE2DR26F57TB
- Not listed
- The Defense Logistics Agency awarded a $35,746.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Spravato 84 mg dose pack unit dose systems. This non-set-aside, competitively awarded contract is scheduled for ultimate completion by January 30, 2026, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a task order issued under AmerisourceBergen's parent company...
- The Defense Logistics Agency awarded a delivery order valued at $1,625.24 to AmerisourceBergen Drug Corp for Spravato 56 mg dose pack unit dose system (UDS) pharmaceutical products. This competitive, non-set-aside contract was awarded on December 22, 2025, with an ultimate completion date of December 23, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Spravato is a specialized nasal spray medication used in the treatment of major...
- On January 12, 2026, the Defense Logistics Agency awarded a delivery order valued at $1,744.15 to AmerisourceBergen Drug Corp for the supply of Spravato 56 mg dose pack unit dose systems. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by January 13, 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with parent company Cencora, Inc. (doing business as AmerisourceBergen)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,829.09 to AmerisourceBergen Drug Corp for the supply of SPRAVATO 84 mg dose pack UDS (unit dose packages). This firm fixed price delivery order, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a non-competitive set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. SPRAVATO (esketamine) is a prescription nasal spray used in treating...
- The Defense Logistics Agency awarded a delivery order valued at $8.55K to AmerisourceBergen Drug Corp for the supply of Spravato 84 mg dose pack UDS (unit dose system) pharmaceutical product. This is a firm fixed price delivery order with no set-aside designation, competitively awarded on December 29, 2025, with an ultimate completion date of December 30, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- This delivery order, valued at $7,553.64, was awarded on January 14, 2026, to AmerisourceBergen Drug Corp for the supply of Spravato 84 mg dose pack unit dose systems. The contract represents a non-set-aside, competitively awarded firm fixed-price delivery order issued by the Defense Logistics Agency (DLA), with performance to be fulfilled from the contractor's Conshohocken, Pennsylvania facility and completion targeted for January 15, 2026. This order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $2,688 to Amerisourcebergen Drug Corporation to supply 4561933884 units of 56 mg doses of Spravato. As the prime contractor, Amerisourcebergen will deliver the medication to a location in Conshohocken, Pennsylvania by August 25, 2023 under the contract start and end dates. The Defense Logistics Agency is the funding agency for this requirement to support its medical supply chain initiatives. No...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of SPRAVATO 84 MG DOSE PACK UDS. The contract has a firm fixed price of $8,057.79 and an ultimate completion date of July 30, 2024. The contract is not designated as a set-aside award. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $9,622.08 contract is for the supply of SPRAVATO 84 MG DOSE PACK UDS, a specialty medication. The contract has a period of performance through September 13, 2024. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, such as a $999,999,999 DLA Troop Support Medical IDC and a $750,000...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $15,328.09 firm fixed-price delivery order is for the supply of SPRAVATO 84 MG DOSE PACK UDS, a pharmaceutical product, with a period of performance through February 22, 2024. The award was not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
- SPE2DR25D2006Indefinite Delivery Contract
- SPE2DR25D2006-SPE2DR26F57TBDelivery Order
The Defense Logistics Agency awarded a $16,784.75 firm fixed-price delivery order to Amerisourcebergen Drug Corp on January 28, 2026, for the supply of Spravato 84 mg dose pack UDS (unit dose system). This non-set-aside competitive award will be completed by January 29, 2026, and is being performed at the contractor's headquarters location in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order operates under Amerisourcebergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which provides a comprehensive vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally. Spravato (esketamine) is a nasal spray medication used in the treatment of major depressive disorder and treatment-resistant depression. The contractor's extensive federal contract portfolio demonstrates consistent capability to fulfill competitive pharmaceutical procurement requirements across multiple therapeutic domains, supported by its substantial IDC relationship with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.8k | 1/27/26 |